z-logo
Premium
Cerebrospinal Fluid Levels of Kininogen‐1 Indicate Early Cognitive Impairment in Parkinson's Disease
Author(s) -
Markaki Ioanna,
Bergström Sofia,
Tsitsi Panagiota,
Remnestål Julia,
Månberg Anna,
Hertz Ellen,
Paslawski Wojciech,
Sorjonen Kimmo,
Uhlén Mathias,
Mangone Graziella,
Carvalho Stephanie,
Rascol Olivier,
Meissner Wassilios G.,
Magnin Eloi,
Wüllner Ullrich,
Corvol JeanChristophe,
Nilsson Peter,
Svenningsson Per
Publication year - 2020
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.28192
Subject(s) - montreal cognitive assessment , dementia , neuropsychology , cognition , psychology , medicine , parkinson's disease , psychiatry , disease
Abstract Background Cognitive impairment is common in patients with PD. Core markers of Alzheimer's dementia have been related also to PD dementia, but no disease‐specific signature to predict PD dementia exists to date. Objectives The aim of this study was to investigate CSF markers associated with cognition in early PD. Methods A high‐throughput suspension bead array examined 216 proteins in CSF of 74 PD patients in the AETIONOMY project. Cognitive function was assessed with Repeatable Battery for the Assessment of the Neuropsychological Status, Montreal Cognitive Assessment, and Mini‐Mental State Examination. Results Of 69 patients with complete data, 34 had high (≥90) and 35 had low Repeatable Battery for the Assessment of the Neuropsychological Status total score (<90). Of 14 proteins in CSF that differed in levels between groups, increased kininogen‐1, validated with several antibodies, was independently associated with lower Repeatable Battery for the Assessment of the Neuropsychological Status and Montreal Cognitive Assessment scores after adjustment for confounders. Conclusions Kininogen‐1 levels in CSF may serve as a marker of cognitive impairment in PD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here